Alitretinoin for the Treatment of Lichen Amyloidosis: A Retrospective, Observational Study and an In Vitro Study

IF 3.4 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-03-20 DOI:10.1155/dth/7835429

Eun Joo Baek, Sun Mee Shin, Seong Jun Kim, Kwang Ho Kim, Kwang Joong Kim, Eun Joo Park

{"title":"Alitretinoin for the Treatment of Lichen Amyloidosis: A Retrospective, Observational Study and an In Vitro Study","authors":"Eun Joo Baek, Sun Mee Shin, Seong Jun Kim, Kwang Ho Kim, Kwang Joong Kim, Eun Joo Park","doi":"10.1155/dth/7835429","DOIUrl":null,"url":null,"abstract":"<div>\n Background: Lichen amyloidosis (LA) is the most common form of localized cutaneous amyloidosis, often accompanied by severe pruritus. Treatment options are limited, and alitretinoin, a systemic retinoid, has shown promise in managing refractory cases.\n Objective: This study aimed to evaluate the efficacy of alitretinoin in treating LA and its effects on keratinocytes.\n Methods: We conducted a retrospective analysis of 13 patients diagnosed with LA treated with alitretinoin. In addition, an in vitro study assessed the impact of alitretinoin on keratinocyte inflammation markers.\n Results: Of the 13 patients, 4 (30.77%) achieved complete clearance of lesions, demonstrating excellent improvement. The remaining 9 (69.23%) showed substantial improvement, with almost clear or mild residual lesions. In vitro, alitretinoin significantly decreased levels of IL-33, periostin, CCL5, and PTGES.\n Conclusion: Alitretinoin demonstrated effectiveness in treating LA, with favorable outcomes in both clinical and in vitro settings. These findings support alitretinoin as a viable treatment option for LA.\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7835429","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/7835429","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lichen amyloidosis (LA) is the most common form of localized cutaneous amyloidosis, often accompanied by severe pruritus. Treatment options are limited, and alitretinoin, a systemic retinoid, has shown promise in managing refractory cases.

Objective: This study aimed to evaluate the efficacy of alitretinoin in treating LA and its effects on keratinocytes.

Methods: We conducted a retrospective analysis of 13 patients diagnosed with LA treated with alitretinoin. In addition, an in vitro study assessed the impact of alitretinoin on keratinocyte inflammation markers.

Results: Of the 13 patients, 4 (30.77%) achieved complete clearance of lesions, demonstrating excellent improvement. The remaining 9 (69.23%) showed substantial improvement, with almost clear or mild residual lesions. In vitro, alitretinoin significantly decreased levels of IL-33, periostin, CCL5, and PTGES.

Conclusion: Alitretinoin demonstrated effectiveness in treating LA, with favorable outcomes in both clinical and in vitro settings. These findings support alitretinoin as a viable treatment option for LA.

Abstract Image

查看原文本刊更多论文

阿利维A治疗地衣淀粉样变性：回顾性、观察性研究和体外研究

背景：地衣淀粉样变（LA）是最常见的局限性皮肤淀粉样变，常伴有严重瘙痒。治疗选择是有限的，阿利维甲酸，一种全身性类维甲酸，在治疗难治性病例中显示出希望。目的：评价阿利维甲酸治疗LA的疗效及其对角质形成细胞的影响。方法：对13例经阿利维甲酸治疗的LA患者进行回顾性分析。此外，一项体外研究评估了阿利维甲酸对角质细胞炎症标志物的影响。结果：13例患者中，4例（30.77%）病灶完全清除，疗效显著。其余9例（69.23%）有明显改善，残余病灶几乎清晰或轻微。在体外，阿利维黄素显著降低IL-33、骨膜蛋白、CCL5和PTGES水平。结论：阿利维甲酸在治疗LA方面显示出有效性，在临床和体外均有良好的结果。这些发现支持阿利维甲酸作为LA的可行治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.